610
Participants
Start Date
July 8, 2022
Primary Completion Date
October 26, 2026
Study Completion Date
October 26, 2026
Inclisiran sodium 300 mg
Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
Placebo
Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
Novartis Investigative Site, Geneva
Novartis Investigative Site, Turnhout
Novartis Investigative Site, Hasselt
Novartis Investigative Site, Genk
Novartis Investigative Site, Chemside
Novartis Investigative Site, Milton
Novartis Investigative Site, Auchenflower
Novartis Investigative Site, Leabrook
Novartis Investigative Site, Yvoir
Novartis Investigative Site, Szeged
Novartis Investigative Site, Lugano
Novartis Investigative Site, Aalst
Icahn School of Med at Mt Sinai, New York
Novartis Investigative Site, Torino
Novartis Investigative Site, Goyang-si
Westchester Medical Center, Valhalla
Novartis Investigative Site, Bundang Gu
Novartis Investigative Site, Córdoba
Novartis Investigative Site, A Coruña
George Washington Univ Medical Ctr, Washington D.C.
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Anderson Medical Research, Ft. Washington
Inova Fairfax Hospital, Falls Church
Virginia Heart, Falls Church
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Toulouse
Inpatient Research Clinical LLC, Miami Lakes
Novartis Investigative Site, Pessac
Heart Center Research Llc, Huntsville
Novartis Investigative Site, Salamanca
Aultman Hospital, Canton
Novartis Investigative Site, Valencia
Reid Physician Associates, Richmond
Minneapolis Heart Institute, Minneapolis
NorthShore University Health System, Evanston
Midwest Heart and Vascular Spec, Overland Park
Novartis Investigative Site, Paris
Soltero Cardiovascular Research Center, Dallas
Orion Medical, Houston
Novartis Investigative Site, Poitiers
R Ins For Heart And Vascular Health, Reno
Cardiovascular Res Found, Beverly Hills
UC San Diego Health, La Jolla
Stanford Health Care, Stanford
Oregon Health Sciences University, Portland
Swedish Medical Center-Cardiovascular Research, Seattle
Univ of Washington Medical Center, Seattle
Alaska Heart and Vascular, Anchorage
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Lucknow
Novartis Investigative Site, Dehradun
Novartis Investigative Site, Chennai
Novartis Investigative Site, Santiago
Lundquist Inst BioMed at Harbor, Torrance
Bridgeport Hospital, Bridgeport
Cardio Metabolic Institute, Somerset
State Uni of NY at Stony Brook, Stony Brook
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Ciudad Autonoma de Bs As
Novartis Investigative Site, Curitiba
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, North York
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Montreal
Novartis Investigative Site, Budapest
Novartis Investigative Site, Bangalore
Novartis Investigative Site, New Delhi
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Coimbatore
Novartis Investigative Site, Dublin
Novartis Investigative Site, Galway
Novartis Investigative Site, Miyhazaki-city
Novartis Investigative Site, Urasoe
Novartis Investigative Site, Izumisano
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Edinburgh
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY